270 related articles for article (PubMed ID: 26498662)
21. Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells.
Liu J; Li J; Sidell N
Cancer Chemother Pharmacol; 2007 Feb; 59(2):217-25. PubMed ID: 16738884
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
23. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
24. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.
McFall T; Patki M; Rosati R; Ratnam M
Oncotarget; 2015 Oct; 6(32):33146-64. PubMed ID: 26356672
[TBL] [Abstract][Full Text] [Related]
25. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
26. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer.
Yu S; Kim T; Yoo KH; Kang K
Biochem Biophys Res Commun; 2017 May; 486(3):752-758. PubMed ID: 28342866
[TBL] [Abstract][Full Text] [Related]
27. Laminin inhibits estrogen action in human breast cancer cells.
Woodward TL; Lu H; Haslam SZ
Endocrinology; 2000 Aug; 141(8):2814-21. PubMed ID: 10919267
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
29. [Western blot analysis and flow cytometric analysis of estrogen and progesterone receptors in fixed breast cancer cells].
Tao DD; Jiang M; Wu JH; Feng YD; Gong JP
Ai Zheng; 2004 Mar; 23(3):339-41. PubMed ID: 15025971
[TBL] [Abstract][Full Text] [Related]
30. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
31. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
32. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
33. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
Sartorius CA; Harvell DM; Shen T; Horwitz KB
Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
[TBL] [Abstract][Full Text] [Related]
34. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
35. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
36. Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells.
Zheng ZY; Zheng SM; Bay BH; Aw SE; C-L Lin V
Breast Cancer Res Treat; 2008 Jul; 110(1):111-25. PubMed ID: 17687644
[TBL] [Abstract][Full Text] [Related]
37. Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75.
Carvajal A; Espinoza N; Kato S; Pinto M; Sadarangani A; Monso C; Aranda E; Villalon M; Richer JK; Horwitz KB; Brosens JJ; Owen GI
Breast Cancer Res Treat; 2005 Nov; 94(2):171-83. PubMed ID: 16175315
[TBL] [Abstract][Full Text] [Related]
38. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.
van Agthoven T; van Agthoven TL; Portengen H; Foekens JA; Dorssers LC
Cancer Res; 1992 Sep; 52(18):5082-8. PubMed ID: 1516065
[TBL] [Abstract][Full Text] [Related]
39. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
40. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]